Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s main product candidate, ZW25, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2 (HER2). The mechanism of action of ZW25 may enable it to address unmet need in patient populations with HER2-expressing cancers. Co.'s second product candidate, ZW49, combines the design of ZW25 with its ZymeLink antibody-drug conjugate (ADC) platform, comprised of its proprietary cytotoxin and cleavable linker. Co. designed ZW49 to be a HER2-targeting ADC to further address unmet need across various HER2-expressing cancers. The ZYME stock yearly return is shown above.
The yearly return on the ZYME stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ZYME annual return calculation with any dividends reinvested as applicable (on ex-dates).
|